Andere Kunden interessierten sich auch für
![Urinary Tract]( "Urinary Tract")
Urinary Tract221,99 €![Dyskinesia]( "Dyskinesia")
Dyskinesia83,99 €![Combined Effects of Drugs and Toxic Agents]( "Combined Effects of Drugs and Toxic Agents")
Combined Effects of Drugs and Toxic Agents42,99 €![Mechanisms of Drug Resistance in Cancer Therapy]( "Mechanisms of Drug Resistance in Cancer Therapy")
Mechanisms of Drug Resistance in Cancer Therapy110,99 €![Rhinitis: Immunopathology and Pharmacotherapy]( "Rhinitis: Immunopathology and Pharmacotherapy")
Rhinitis: Immunopathology and Pharmacotherapy160,49 €![Mechanisms in Carcinogenesis and Cancer Prevention]( "Mechanisms in Carcinogenesis and Cancer Prevention")
Mechanisms in Carcinogenesis and Cancer Prevention295,99 €![Rhinitis: Immunopathology and Pharmacotherapy]( "Rhinitis: Immunopathology and Pharmacotherapy")
Rhinitis: Immunopathology and Pharmacotherapy125,99 €
This book is a comprehensive, concise summary of the pharmacological treatments of prostate cancer. It is an authoritative and up-to-date reference on therapeutic options involving both standard of care and investigational agents. The chapters describe state of the art information on Hormone Therapy, Chemotherapy, Angiogenesis, Therapy for Bone Metastases, Immunotherapy, Prevention, and Drug Development. Drug Management of Prostate Cancer is an excellent resource for medical oncologists, trainees, researchers, and members of the pharmaceutical industry.
Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges' report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptorand/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.
Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges' report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptorand/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.
From the reviews:
"For medical oncologists, trainees, researchers, and those in the pharmaceutical industry, Figg ... offer a comprehensive and concise summary of the pharmacological treatments for prostate cancer, both current standard and investigative options. The 36 chapters ... focus on a multidisciplinary care approach and cover hormone therapy, chemotherapy, angiogenesis, therapy for bones metastases, immunotherapy, chemoprevention, and drug development. Cell biology and molecular targets are also discussed." (SciTech Book News, December, 2010)
"The 36 chapters in this book ... read as independent discussions of many of the most recent discoveries in the area of drug management of prostate cancer. ... suitable for medical students, physicians in training, physicians (especially medical oncologists), scientists, translational researchers, and members of the pharmaceutical industry. ... An important aspect of this book is that the data represents updated, state-of-the-art information, making it valuable for daily reference. ... an excellent resource for readers interested in the management of advanced prostate cancer ... ." (Jianqing Lin, Doody's Review Service, December, 2010)
"This treatise is an exhaustive description of the application of drug management of prostate cancer involving both standard care and investigational agents. ... this book will give the reader a detailed insight about the current knowledge from clinical trials into the drug treatment of prostate tumours. The urologists, medical oncologist and others involved in the treatment of the prostate cancer will find in this work a complete review of where we are now." (M. Hornák, Neoplasma, March, 2011)
"This textbook by W.D. Figg and co-authors ... makes an exhaustive overview of present and future medical therapies of prostate cancer. ... This book provides the reader with comprehensive information about pharmacological treatments of prostate cancer. All chapters are concise and most ofthem are well-illustrated. We recommend this textbook to urologists, oncologists who are involved in prostate cancer management, and to all physicians and students who want to update their knowledge in prostate cancer management." (European Urology Today, April/May, 2011)
"For medical oncologists, trainees, researchers, and those in the pharmaceutical industry, Figg ... offer a comprehensive and concise summary of the pharmacological treatments for prostate cancer, both current standard and investigative options. The 36 chapters ... focus on a multidisciplinary care approach and cover hormone therapy, chemotherapy, angiogenesis, therapy for bones metastases, immunotherapy, chemoprevention, and drug development. Cell biology and molecular targets are also discussed." (SciTech Book News, December, 2010)
"The 36 chapters in this book ... read as independent discussions of many of the most recent discoveries in the area of drug management of prostate cancer. ... suitable for medical students, physicians in training, physicians (especially medical oncologists), scientists, translational researchers, and members of the pharmaceutical industry. ... An important aspect of this book is that the data represents updated, state-of-the-art information, making it valuable for daily reference. ... an excellent resource for readers interested in the management of advanced prostate cancer ... ." (Jianqing Lin, Doody's Review Service, December, 2010)
"This treatise is an exhaustive description of the application of drug management of prostate cancer involving both standard care and investigational agents. ... this book will give the reader a detailed insight about the current knowledge from clinical trials into the drug treatment of prostate tumours. The urologists, medical oncologist and others involved in the treatment of the prostate cancer will find in this work a complete review of where we are now." (M. Hornák, Neoplasma, March, 2011)
"This textbook by W.D. Figg and co-authors ... makes an exhaustive overview of present and future medical therapies of prostate cancer. ... This book provides the reader with comprehensive information about pharmacological treatments of prostate cancer. All chapters are concise and most ofthem are well-illustrated. We recommend this textbook to urologists, oncologists who are involved in prostate cancer management, and to all physicians and students who want to update their knowledge in prostate cancer management." (European Urology Today, April/May, 2011)